Experimental cancer drug CPO-100 trial halted early

NCT ID NCT04931823

Terminated Disease control Sponsor: Conjupro Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm gastric neoplasm Head and Neck Neoplasms lung neoplasm neoplasm Neoplasm Metastasis ovarian cancer prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Carolina BioOncology Institute

Huntersville, North Carolina, 28078, United States
Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89169, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States
The Cleveland Clinic Foundation

Lyndhurst, Ohio, 44124, United States
University of California Los Angeles

Los Angeles, California, 75246, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States
Virginia Cancer Specialist

Fairfax, Virginia, 22031, United States
Yale University School of Medicine - Yale Cancer Center

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.